Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Enliven Therapeutics, Inc.
NASDAQ:ELVNHealthcare · Biotechnology
-1.84%$44.25
AH$44.25+0.00%vs close
Mkt Cap$3.24B
Float56.95M
O/S73.27M
Vol
$ Vol
RVOL
Inst Own-
SI16.4%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$103.69M
Total Assets$476.17M
Free Cash Flow-$70.46M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$399K
Total Equity$459.6M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in ELVN's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$476.17M
Liabilities$16.68M
Accounts Receivable$0
Accounts Payable$2.16M
Inventory$0
PP&E (Net)$417K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $263K | $0 | $0 | $0 | $0 | $0 | $33K | $0 | $0 |
| Gross Profit | -$263K | $0 | $0 | $0 | $0 | $0 | -$33K | $0 | $0 |
| Gross Margin | - | - | - | - | - | - | - | - | - |
| Research and Development | $85.86M | $80.78M | $64.57M | $31.02M | $20.47M | $8.24M | $19.01M | $8.24M | $7.92M |
| Selling, General, and Administrative | $33.8M | $23.78M | $18.95M | $7.77M | $4.29M | $1.08M | $5.07M | $2.44M | $987K |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $119.39M | $104.55M | $83.53M | $38.79M | $24.76M | $9.32M | $24.08M | $10.68M | $8.9M |
| Operating Income (EBIT) | -$119.66M | -$104.55M | -$83.53M | -$38.79M | -$24.76M | -$9.32M | -$24.12M | -$10.68M | -$8.9M |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $16.01M | $14.89M | $11.97M | $1.13M | $22K | $483K | $578K | $0 | $0 |
| Other Income (Expense) | $15.96M | $15.76M | $11.95M | $1.13M | $22K | -$9.65M | $653K | -$660K | $9.13M |
| Income Before Tax (EBT) | -$103.69M | -$88.79M | -$71.58M | -$37.66M | -$24.74M | -$18.97M | -$23.46M | -$11.34M | $221K |
| Income Tax Expense | $0 | $232K | $0 | $0 | $0 | $0 | $0 | $0 | $221K |
| Net Income | -$103.69M | -$89.02M | -$71.58M | -$37.66M | -$24.74M | -$18.97M | -$23.46M | -$11.34M | $0 |
| Net Income Margin | - | - | - | - | - | - | - | - | - |
| Supplementary Data | |||||||||
| EPS | -1.83 | -1.89 | -2.01 | -6.03 | -3.17 | -4.31 | -5.43 | -2.62 | 0.00 |
| Diluted EPS | -1.83 | -1.89 | -2.01 | -6.03 | -3.17 | -4.31 | -5.43 | -2.62 | 0.00 |
| Weighted Average OS | 56.66M | 47.07M | 35.55M | 6.25M | 7.81M | 4.39M | 4.32M | 4.32M | 4.32M |
| EBITDA | -$103.43M | -$88.47M | -$71.29M | -$37.45M | -$24.63M | -$9.27M | -$23.43M | -$11.34M | $221K |
| EBITDA Margin | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and Cash Equivalents | $98.9M | $124.12M | $100.14M | $75.54M | $110.02M | $47.7M | $4.94M | $7.38M | $9.67M |
| Short-Term Investments | $363.73M | $189.32M | $153.01M | $0 | $0 | $40.52M | $23.97M | $0 | $0 |
| Cash and Short-Term Investments | $462.62M | $313.44M | $253.15M | $75.54M | $110.02M | $88.22M | $28.91M | $7.38M | $9.67M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $12.26M | $4.69M | $10.05M | $2.22M | $0 | $2.18M | $1.72M | $323K | $552K |
| Total Current Assets | $474.88M | $318.13M | $266.15M | $77.75M | $110.67M | $90.41M | $30.62M | $7.71M | $10.22M |
| Long-Term Assets | |||||||||
| Property, Plant & Equipment Net | $417K | $458K | $1.06M | $1.52M | $954K | $349K | $442K | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $54K | $0 | $0 | $88K | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $873K | $7.17M | $4.65M | $3.98M | $1.71M | $88K | $2.14M | $0 | $0 |
| Total Long-Term Assets | $1.29M | $7.63M | $5.72M | $5.54M | $2.66M | $437K | $2.67M | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $476.17M | $325.76M | $271.87M | $83.3M | $113.33M | $90.84M | $33.3M | $7.71M | $10.22M |
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payable | $2.16M | $1.34M | $532K | $3.44M | $2.52M | $1.97M | $1.66M | $908K | $431K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $5.51M | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $4.65M | $204K | $10.36M | $320K | $233K | $3.19M | $1.74M | $787K | $196K |
| Total Current Liabilities | $16.57M | $15.91M | $25.89M | $9.71M | $5.75M | $6.25M | $4.2M | $1.83M | $826K |
| Long-Term Liabilities | |||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $660K |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $108K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $67K | $150.41M | $714K | $160K | $184K | $32.19M | $0 |
| Total Long-Term Liabilities | $108K | $0 | $67K | $150.41M | $714K | $160K | $184K | $32.19M | $660K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$32.19M | $0 |
| Total Liabilities | $16.68M | $15.91M | $25.96M | $160.12M | $6.47M | $6.41M | $4.38M | $1.83M | $1.49M |
| Stockholders' Equity | |||||||||
| Preferred Stock | $0 | $0 | $0 | $150K | $149.75M | $0 | $0 | $0 | $0 |
| Common Stock | $59K | $49K | $41K | $1K | $1K | $18K | $4K | $4K | $4K |
| Retained Earnings | -$347.17M | -$243.47M | -$154.45M | -$82.86M | -$45.2M | -$96.11M | -$54.75M | -$31.29M | -$19.95M |
| Comprehensive Income & Other | $334K | $55K | $141K | -$150K | $0 | $4K | $32K | $0 | $0 |
| Other Stockholders' Equity | $806.71M | $553.27M | $400.31M | $6.04M | $152.06M | $180.53M | $5.9M | $4.97M | $4.42M |
| Total Equity | $459.6M | $309.85M | $245.91M | -$76.83M | $106.86M | $84.44M | -$48.85M | -$26.32M | -$15.53M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $476.28M | $325.76M | $271.87M | $83.3M | $113.33M | $90.84M | -$44.47M | -$24.48M | -$14.05M |
| Supplementary Data | |||||||||
| Total Debt | $399K | $0 | $335K | $323K | $159K | $0 | $0 | $0 | $660K |
| Net Debt | -$98.5M | -$124.12M | -$99.81M | -$75.21M | -$109.86M | -$47.7M | -$4.94M | -$7.38M | -$9.01M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Operating Activities | |||||||||
| Net Income | -$103.69M | -$89.02M | -$71.58M | -$37.66M | -$24.74M | -$18.97M | -$23.46M | -$11.34M | $0 |
| Depreciation & Amortization | $263K | $317K | $297K | $215K | $115K | $45K | $33K | $0 | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | -$3.81M | $0 | -$215K | $0 | $0 |
| Stock-Based Compensation | $34.02M | $20.17M | $12.91M | $3.19M | $1.92M | $130K | $899K | $555K | $0 |
| Changes in Working Capital: | |||||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $817K | $810K | -$2.25M | $411K | $1.73M | $291K | $750K | $477K | -$666K |
| Other Working Capital | -$1.94M | -$5.35M | $3.65M | $27K | $1.83M | $292K | -$77K | $758K | $478K |
| Total Working Capital Change | -$1.12M | -$4.54M | $1.4M | $438K | $3.57M | $583K | $673K | $1.24M | -$188K |
| Other Non-Cash Items | $232K | -$118K | -$4.3M | $1.74M | $3.81M | $9.68M | $196K | $848K | -$7.93M |
| Net Cash from Operating | -$70.3M | -$73.19M | -$61.27M | -$32.08M | -$19.13M | -$8.53M | -$21.88M | -$8.78M | -$8.79M |
| Investing Activities | |||||||||
| Capital Expenditures | -$158K | -$44K | -$149K | -$612K | -$191K | -$461K | -$140K | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $35M | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$446.79M | -$350.74M | -$268.26M | -$35M | -$47.56M | -$64.2M | -$23.92M | $0 | $0 |
| Sales of Investments | $272.9M | $313.91M | $120M | $41.88M | $45.94M | $47.5M | $0 | $0 | $0 |
| Other Investing Activities | $213K | $873K | $0 | -$41.88M | $1.62M | $16.7M | $0 | $0 | $0 |
| Net Cash from Investing | -$173.84M | -$36M | -$148.41M | -$612K | -$191K | -$461K | -$24.06M | $0 | $0 |
| Financing Activities | |||||||||
| Debt Repaid | - | - | - | - | - | - | $2M | - | - |
| Common Stock Issuance | $218.87M | $39.19M | $161.2M | -$1.23M | -$1.02M | $96.88M | $45.58M | $6.49M | $11M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $93.98M | $73.08M | -$566K | $0 | $33.63M | $0 | $6.49M | $11M |
| Net Cash from Financing | $218.87M | $133.16M | $234.29M | -$1.8M | -$1.02M | $130.51M | $43.58M | $6.49M | $11M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | -$88K | $0 | $0 |
| Net Change in Cash | -$25.27M | $23.98M | $24.61M | -$34.49M | -$20.34M | $121.52M | -$2.45M | -$2.29M | $2.21M |
| Supplementary Data | |||||||||
| Operating Cash Flow | -$70.3M | -$73.19M | -$61.27M | -$32.08M | -$19.13M | -$8.53M | -$21.88M | -$8.78M | -$8.79M |
| Capital Expenditure | -$158K | -$44K | -$149K | -$612K | -$191K | -$461K | -$140K | $0 | $0 |
| Free Cash Flow | -$70.46M | -$73.24M | -$61.42M | -$32.69M | -$19.32M | -$8.99M | -$22.02M | -$8.78M | -$8.79M |
| Cash at Beginning | $124.17M | $100.19M | $75.59M | $110.08M | $130.42M | $8.9M | $7.38M | $9.67M | $7.46M |
| Cash at End | $98.9M | $124.17M | $100.19M | $75.59M | $110.08M | $130.42M | $4.94M | $7.38M | $9.67M |